SNS-101
Phase 1- Indications
- Solid tumors
Company intelligence / Profile preview
Sensei Biotherapeutics
Rockville, Maryland, United Statessenseibio.com ↗
- Ownership
- Public · SNSE
- Development stage
- Phase 1
01
Overview
Sensei's lead product candidate solnerstotug (SNS-101) has shown promising clinical activity in a Phase 1/2 trial with a favorable safety profile. The drug targets VISTA selectively within the low pH tumor microenvironment. The company has completed target enrollment (n=60) in the dose expansion cohort with full expansion data expected by year-end 2025[5][9].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesconditionally active antibodiesbacteriophage-based immunotherapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Regeneron PharmaceuticalsNational Cancer Institute (NCI)
Beyond the preview
Go deeper on Sensei Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sensei Biotherapeutics.